Literature DB >> 2790702

Cell kinetics and hormonal receptor status in inflammatory breast carcinoma. Comparison with locally advanced disease.

A Paradiso1, S Tommasi, M Brandi, F Marzullo, G Simone, V Lorusso, A Mangia, M De Lena.   

Abstract

The biological and prognostic role of hormone receptor status and proliferative activity have been studied in two series of patients affected by inflammatory breast carcinoma (IBC, 28 patients) and locally advanced breast cancer (LABC, 50 patients). Estrogen receptor (ER) and progesterone receptor (PgR) were measured by dextran-coated charcoal (DCC) method whereas proliferative activity was measured by 3H-thymidine autoradiographic labeling index (LI). The percentages of ER+ and PgR+ cases resulted lower in IBC than in LABC (ER+, 44% versus 64%; PgR+, 30% versus 51%, respectively), pertaining to both premenopausal and postmenopausal women. Inflammatory breast carcinoma showed a higher median LI value than LABC (3.5% versus 1.6%; P = 0.006). Regarding clinical aspects, time to progression (TTP) in IBC patients was not affected by hormone receptor status (19 evaluable patients) or by LI (17 evaluable patients); PgR+ status and low LI resulted important for individualizing women with a longer median overall survival (OS). Inflammatory breast carcinoma has been verified to be a heterogeneous biological entity for which hormone receptors and cell kinetics could be useful in identifying patients with different prognoses and therefore candidates for a personalized therapy.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2790702     DOI: 10.1002/1097-0142(19891101)64:9<1922::aid-cncr2820640927>3.0.co;2-i

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  12 in total

1.  Inflammatory breast cancer: the experience of Baylor University Medical Center at Dallas.

Authors:  Justin M Goldfarb; John E Pippen
Journal:  Proc (Bayl Univ Med Cent)       Date:  2011-04

2.  The current understanding of the molecular determinants of inflammatory breast cancer metastasis.

Authors:  Galina S Radunsky; Kenneth L van Golen
Journal:  Clin Exp Metastasis       Date:  2006-04-27       Impact factor: 5.150

Review 3.  Management of inflammatory breast cancer.

Authors:  S E Singletary; F C Ames; A U Buzdar
Journal:  World J Surg       Date:  1994 Jan-Feb       Impact factor: 3.352

4.  Cytosol cathepsin-D content and proliferative activity of human breast cancer. The Comitato Italiano per il Controllo di Qualita del Laboratorio in Oncologia.

Authors:  A Paradiso; A Mangia; M Correale; I Abbate; G Ferri; A Piffanelli; L Catozzi; D Amadori; A Riccobon; M De Lena
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

5.  Alternate estrogen receptors promote invasion of inflammatory breast cancer cells via non-genomic signaling.

Authors:  Kazufumi Ohshiro; Arnold M Schwartz; Paul H Levine; Rakesh Kumar
Journal:  PLoS One       Date:  2012-01-25       Impact factor: 3.240

Review 6.  Molecular biology of breast cancer metastasis. Inflammatory breast cancer: clinical syndrome and molecular determinants.

Authors:  C G Kleer; K L van Golen; S D Merajver
Journal:  Breast Cancer Res       Date:  2000-07-11       Impact factor: 6.466

7.  NF-kappa B genes have a major role in inflammatory breast cancer.

Authors:  Florence Lerebours; Sophie Vacher; Catherine Andrieu; Marc Espie; Michel Marty; Rosette Lidereau; Ivan Bieche
Journal:  BMC Cancer       Date:  2008-02-04       Impact factor: 4.430

Review 8.  Inflammatory breast cancer: clinical progress and the main problems that must be addressed.

Authors:  Sharon H Giordano; Gabriel N Hortobagyi
Journal:  Breast Cancer Res       Date:  2003-08-26       Impact factor: 6.466

Review 9.  Update on inflammatory breast cancer.

Authors:  Florence Lerebours; Ivan Bieche; Rosette Lidereau
Journal:  Breast Cancer Res       Date:  2005-01-20       Impact factor: 6.466

10.  The Impact of Subtype Distribution in Inflammatory Breast Cancer Outcome.

Authors:  Burcu Çakar; Zeki Sürmeli; Pınar Gürsoy Öner; Elif Sıla Yelim; Bülent Karabulut; Ruchan Uslu
Journal:  Eur J Breast Health       Date:  2018-10-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.